Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Myelodysplastic Syndromes 21Leukemia, Myeloid, Acute 16Leukemia, Myelomonocytic, Chronic 11Myeloproliferative Disorders 4Myelodysplastic-Myeloproliferative Diseases 2Anemia, Refractory, with Excess of Blasts 2Thrombocythemia, Essential 1Systemic Mastocytosis With an Associated Hematologic Neoplasm 1Primary Myelofibrosis 1Polycythemia Vera 1Patient Preference 1Multiple Myeloma 1Leukemia, Biphenotypic, Acute 1GATA2 Deficiency 1Colorectal Neoplasms 1Accelerated Phase Myeloproliferative Neoplasm 1

Interventions

decitabine and cedazuridine drug combination 1Injections 1Decitabine 1Azacitidine 111-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Accelerated Phase Myeloproliferative Neoplasm × decitabine and cedazuridine drug combination × Myeloid × Clear all
NCT07148947 2026-03-04

Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms

University of Washington

Phase 2 Recruiting
27 enrolled
Myeloid

Accelerated Phase Myeloproliferative Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡